IDH2 and central nervous system cancer: While mutation of both IDH1 and IDH2 isoforms are observed in a range of cancers [56], IDH1 R132H represents the main mutation (90%) in sporadic IDH mutant gliomas [57] and is associated with more favorable outcomes.